The Department of Health and Human Services Oct. 2 released final guidance detailing the process for the second cycle of negotiations under the Medicare Drug Price Negotiation Program. It also explains how the Centers for Medicare & Medicaid Services will help ensure Medicare beneficiaries can access drugs at the negotiated prices from the first and second cycles when those prices become effective in 2026 and 2027, respectively. CMS in August announced lower prices for 10 drugs covered by Part D that were selected in the first round. AHA in July commented on the guidance for the program, expressing concern about CMS’ proposal to retrospectively effectuate access to the negotiated prices and its implications for the 340B program. AHA will share more information soon about specific implications of the final guidance for hospitals. 

Related News Articles

Headline
The federal government shutdown will continue as the Senate Oct. 3 failed to adopt a government funding deal. The latest attempt to pass the House-passed…
Headline
The Centers for Medicare & Medicaid Services Sept. 30 issued a memo, through the Health Plan Management system, finalizing the Medicare Advantage…
Headline
The federal government shut down Oct. 1 following a failed Senate vote on the House-passed continuing resolution to fund the government by midnight Sept. 30.…
Headline
President Trump today announced the first agreement with a major pharmaceutical company, Pfizer, to bring American drug prices in line with the lowest paid by…
Headline
The AHA Sept. 29 sent recommendations to the Department of Health and Human Services and the Centers for Medicare & Medicaid Services to help ensure…
Headline
The Centers for Medicare & Medicaid Services announced Sept. 26 that average premiums for Medicare Advantage and Part D would decline slightly in 2026.…